X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ABBOTT INDIA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ABBOTT INDIA AUROBINDO PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 17.9 32.5 54.9% View Chart
P/BV x 5.8 8.1 71.4% View Chart
Dividend Yield % 0.4 0.8 43.2%  

Financials

 AUROBINDO PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-16
ABBOTT INDIA
Mar-16
AUROBINDO PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,5416,015 25.6%   
Low Rs5823,707 15.7%   
Sales per share (Unadj.) Rs237.51,236.9 19.2%  
Earnings per share (Unadj.) Rs33.9122.2 27.7%  
Cash flow per share (Unadj.) Rs40.6129.0 31.5%  
Dividends per share (Unadj.) Rs2.5035.00 7.1%  
Dividend yield (eoy) %0.20.7 32.7%  
Book value per share (Unadj.) Rs120.6521.2 23.1%  
Shares outstanding (eoy) m585.1721.25 2,753.7%   
Bonus/Rights/Conversions PREF--  
Price / Sales ratio x4.53.9 113.7%   
Avg P/E ratio x31.339.8 78.8%  
P/CF ratio (eoy) x26.237.7 69.4%  
Price / Book Value ratio x8.89.3 94.4%  
Dividend payout %7.428.6 25.8%   
Avg Mkt Cap Rs m621,041103,296 601.2%   
No. of employees `00013.33.0 449.5%   
Total wages/salary Rs m15,5083,370 460.2%   
Avg. sales/employee Rs Th10,457.68,891.8 117.6%   
Avg. wages/employee Rs Th1,167.11,140.0 102.4%   
Avg. net profit/employee Rs Th1,491.6878.3 169.8%   
INCOME DATA
Net Sales Rs m138,96126,284 528.7%  
Other income Rs m1,663504 329.6%   
Total revenues Rs m140,62426,789 524.9%   
Gross profit Rs m32,0563,665 874.5%  
Depreciation Rs m3,926144 2,718.9%   
Interest Rs m2,5688 31,698.8%   
Profit before tax Rs m27,2254,017 677.7%   
Minority Interest Rs m390-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,4441,421 523.8%   
Profit after tax Rs m19,8202,596 763.4%  
Gross profit margin %23.113.9 165.4%  
Effective tax rate %27.335.4 77.3%   
Net profit margin %14.39.9 144.4%  
BALANCE SHEET DATA
Current assets Rs m100,01514,446 692.3%   
Current liabilities Rs m74,7594,725 1,582.3%   
Net working cap to sales %18.237.0 49.1%  
Current ratio x1.33.1 43.8%  
Inventory Days Days10751 208.9%  
Debtors Days Days11020 560.3%  
Net fixed assets Rs m52,3501,113 4,704.0%   
Share capital Rs m585213 275.4%   
"Free" reserves Rs m67,70710,808 626.5%   
Net worth Rs m70,56711,076 637.1%   
Long term debt Rs m8,4720-   
Total assets Rs m156,99416,241 966.7%  
Interest coverage x11.6497.0 2.3%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.91.6 54.7%   
Return on assets %14.316.0 88.9%  
Return on equity %28.123.4 119.8%  
Return on capital %37.736.3 103.9%  
Exports to sales %51.00.6 8,301.8%   
Imports to sales %18.812.6 149.1%   
Exports (fob) Rs m70,927162 43,890.3%   
Imports (cif) Rs m26,1933,322 788.4%   
Fx inflow Rs m71,015268 26,498.2%   
Fx outflow Rs m28,7993,927 733.3%   
Net fx Rs m42,216-3,659 -1,153.6%   
CASH FLOW
From Operations Rs m17,5962,514 699.8%  
From Investments Rs m-13,801-800 1,726.2%  
From Financial Activity Rs m-198-803 24.7%  
Net Cashflow Rs m3,597912 394.4%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.0 7.9 100.6%  
FIIs % 27.7 0.1 27,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.1 59.6%  
Shareholders   69,601 18,270 381.0%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  NOVARTIS  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; Auto Stocks Witness Selling(01:30 pm)

After opening the day flat, share markets in India continued to witness selling pressure and are currently trading in red. Sectoral indices are trading on a mixed note with stocks in the metals sector.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 21, 2017 02:12 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS